Jury asked for mesothelioma warning on J&J talc products

25 May 2018 by under Legal

talcum powder warning 2 products 300x172 Jury asked for mesothelioma warning on J&J talc productsA California jury that awarded $21.7 million in compensatory damages to a woman whose claimed the talc in ’s products was contaminated with asbestos that caused her to develop the rare and aggressive form of cancer called mesothelioma, paused during deliberations on punitive damages to ask the court whether, in lieu of monetary damages, jurors could punish the company by requiring it to place warning labels on its talc-containing products. Read the rest of this entry »


J&J hit with $21.7 million in compensatory damages in talc mesothelioma trial

25 May 2018 by under Legal

talc justice 100x100 J&J hit with $21.7 million in compensatory damages in talc mesothelioma trialA California jury slapped Johnson & Johnson with a $21.7 million in compensatory damages in a trial alleging the consumer health care giant’s talcum powder products were tainted with and caused a woman to develop malignant mesothelioma. The jury is currently deliberating over punitive damages. Read the rest of this entry »


Woman blames J&J talc for causing rare mesothelioma

24 May 2018 by under Legal

talc justice 100x100 Woman blames J&J talc for causing rare mesotheliomaSince the day Bertila Boyd-Bostic came home from the hospital as a newborn, she was sprinkled with Johnson’s Baby Powder. Every day, multiple times a day, she was powdered – after every diaper change and every bath. When she was diagnosed with an extremely rare and deadly form of cancer caused by exposure, she and her husband and law partner Antoine filed a lawsuit against several companies, including the baby powder maker, Johnson & Johnson. She claimed the consumer health care giant used talc that was contaminated with , which led to her disease. Read the rest of this entry »


Combination therapy doubles survival in mice with mesothelioma

21 May 2018 by under Research/Treatment

research test tubes 100x100 Combination therapy doubles survival in mice with mesotheliomaCombining two cancer immunotherapy drugs – a novel immune modulator and a therapy that activates the anti-tumor immune response – more than doubled survival in laboratory mice with malignant mesothelioma, according to a report published in Cancer Immunology Research. Read the rest of this entry »


J&J to keep talc in its baby products despite asbestos concerns

18 May 2018 by under News

640px Talc mutnikSVK01 100x100 J&J to keep talc in its baby products despite asbestos concerns’s consumer health care division is relaunching its line of baby care products, removing concerning ingredients like dyes and sulfates and replacing mineral oil with coconut oil in an effort to appeal to ingredient-conscious millennial moms. But it isn’t touching the talc in its Johnson’s Baby Powder. In fact, the company is adding a new talc-containing product – one that combines talc with cotton. Read the rest of this entry »


Supreme Court to hear appeal of asbestos exposure case

16 May 2018 by under Legal

Lady justice Dublin L 100x100 Supreme Court to hear appeal of asbestos exposure caseThe U.S. Supreme Court will hear the appeal of a Third Circuit decision in two consolidated lawsuits that held companies accountable under maritime law for -related injuries if the companies could have reasonably known that was added to their products by third parties, according to Law360. Read the rest of this entry »


Immunotherapy an option for patients with recurrent pleural mesothelioma

14 May 2018 by under Research/Treatment

Diagram showing a build up of fluid in the lining of the lungs pleural effusion CRUK 0541 100x100 Immunotherapy an option for patients with recurrent pleural mesotheliomaA French study has found that immunotherapy may be effective in treating people with malignant pleural mesothelioma (MPM) that has recurred after standard chemotherapy. The treatment involved the use of two immunotherapy treatment plans – nivolumab (Opdivo) or a combination of nivolumab and ipilimumab (Yervoy). Read the rest of this entry »


Annual ADAO conference works to eradicate asbestos exposure

11 May 2018 by under Events

adao logo Annual ADAO conference works to eradicate asbestos exposureThe Asbestos Disease Awareness Organization (ADAO) held its 14th annual conference last month bringing together experts, survivors, unions and lawmakers from around the world to connect and share the latest education, advocacy and community support efforts.

The 2018 conference featured 30 experts from nine countries, and is the only annual conference dedicated solely to preventing exposure and eliminating -causing diseases. Attendees had the opportunity to connect with leaders and influencers in the prevention community, as well as victims of exposure and family members. Read the rest of this entry »


Study to examine experimental drug in patients with pleural mesothelioma

9 May 2018 by under Research/Treatment

research test tubes 100x100 Study to examine experimental drug in patients with pleural mesotheliomaMemorial is conducting a study to determine if adding an investigational drug to standard-of-care chemotherapy is more effective at extending lifespan in patients with malignant pleural mesothelioma.

The randomized, double-blind, phase II/III study, called POLAIS2015-003, is recruiting patients with malignant with low argininosuccinate synthetase I expression. Aginine is a nutrient that makes up proteins. Laboratory studies show that ADI-PEG 20 can break down arginine, which can destroy cancer cells. Researchers want to determine if combining this experimental drug with stand-of-care chemotherapies is better than chemotherapy alone. Read the rest of this entry »


Experimental mesothelioma vaccine posts promising results

7 May 2018 by under Research/Treatment

syringe vaccine 100x100 Experimental mesothelioma vaccine posts promising resultsBiotech company reported positive results from a limited, Phase I/II clinical study involving its oncolytic virus platform ONCOS-102 and standard-of-care chemotherapy (pemetrexed/cisplatin) in patients with unresectable malignant pleural mesothelioma. After six months, tumor sizes were successfully reduced in three out of six patients treated with the experimental therapy. One patient had a partial response, and the disease was stable in the remaining two patients. Read the rest of this entry »